OBJECTIVES To study the incidence of atorvastatin-induced abnormal liver function in Chinese patients.
RESULTS According to our searching strategy and including criteria, 2386 literatures (2298 Chinese literatures and 88 English ones) published between 2001 and 2015 were included, among which there were 1984 RCT studies, 45 cohort studies, 258 case series studies and 99 quasi-experiment studies. 1140 literatures reported the adverse drug reactions (ADRs) in the process of follow-up, but 1246 literatures did not explicitly mentioned any ADRs. 182430 patients with different diseases such as coronary heart disease, acute coronary syndromes, unstable angina pectoris, hyperlipidemia, atherosclerosis were analyzed. The maximum treatment time was 7 years. Based on the studies reported ADRs (1140 literatures), the numbers of patients in 10mg/d, 20mg/d, 40mg/d and 80mg/d groups were 29079, 54020, 9255 and 1216, respectively, and the corresponding incidence and 95%CI of atorvastatin-induced abnormal liver function were 1.1% (0.9%w1.2%), 1.2% (1.1%w1.3%), 1.3% (1.1%w1.5%) and 2.7% (1.4%w 3.9%), respectively. There were no significant differences among different treatment periods in the same dose group. Based on all 2386 literatures, the numbers of patients were 52030, 106009, 18840 and 3352 in four groups, respectively, and corresponding incidence of atorvastatin-induced abnormal liver function were 0.6% (0.5%w 0.7%), 0.03% (0.02%w0.05%), 0.6% (0.5%w0.7%) and 0.9% (0.6%w 1.2%) with the assume that those studies not mentioned ADRs were the ones with no ADRs. When based on hepatic transaminases > 3 times the upper limit of normal in literatures reported ADRs, the incidence and 95%CI of atorvastatin-induced hepatitis were 0.9% (0.6%w1.1%), 0.9% (0.7%w1.1%), 1.0% (0.6%w1.3%) and 1.4% (0.2%w2.5%) in 10mg/d, 20mg/d, 40mg/d and 80mg/d groups, respectively. In addition, there were 6, 1, 10 and 17 literatures described 5mg/d, 15mg/d, 30mg/d and 60mg/d, respectively, and with few cases of abnormal liver function in each groups (2/566, 1/64, 11/592 and 14/977, respectively).
CONCLUSIONS The incidence of atorvastatin-induced abnormal liver function in Chinese patients were very low.
GW26-e0730
Effect of phosphocreatine on angiotensininIIinduced proliferation and collagen synthesis in neonatal rat cardiac fibroblasts Zihan Wei, Ying Wang the First Affiliated Hospital, Zhengzhou University OBJECTIVES The aim of this study is to investigate the effect of phosphocreatine (PCr) on angiotensinII(AngII)-induced cardiac fibroblasts in neonatal rats in vitro and to clarify its mechanismof action.
METHODS The model of myocardial fibrosis induced by AngIIwas established, the effect of phosphocreatine on cultured cardiac fibroblasts(CF) proliferation in the presence or absence of excessive angiotensinII(AngII) was assessed by flow cytometric assay, the area of myocardial collagen was observed by VG staining and the expression of the phosphorylated extracellular signal-regulated kinase (pERK1/2) was detected by immunohistochemistry in each group. The cardiac fibroblasts were randomly divided into four groups: ① the control group ② the AngII group (1Â10 -6 mol/L) ③ the phosphocreatine treated group (10mmol/L) ④ the AngII þphosphocreatine treated group (1Â10 -6 mol/L þ10mmol/L).
RESULTS
The model of myocardial fibrosis was successfully established. Compared to the control group, distribution of CFs in G 0 /G 1 and G 2 /M phase in AngIIgroup was decreased (P<0.01) with conversely, the increase of the proporation in S phase, the collagen synthesis and the expression of pERK1/2 protein of CFs(P<0.01). However, no significant difference was observed in cell cycle distribution, collagen synthesis of CFs and the expression of pERK1/2 protein between the control and the phosphocreatine treated group(P>0.05). Compared to the AngIIgroup, the percentage of CFs in the G 0 /G 1 phase and G 2 /M phase was increased with simultaneously, the reduction of S phase and the collagen synthesis in AngIIþphosphocreatine treated group (P<0.01). Noteworthy, phospho-status of ERK1/2 in the AngIIþphosphocreatine treated group demonstrated a higher expression than that in the control group as well as lower than in the AngIIgroup (P<0.01).
CONCLUSIONS Our study shows that phosphocreatine plays a crucial role in the inhibition of myocardial fibrosis induced by AngIIthrough partially suppressing the CF proliferation and collagen synthesis, which is possibly associated with the inhibition of excessively activated ERK1/2.
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A research on initial dosage of warfarin and target ratio Guo Huijun, Xiuchun Yang, Jingchao Lu, Fan Liu Second Hospital of Hebei Medical University OBJECTIVES To further acknowledge the optimal initial dosage and offer more reasonable evidence for the application of warfarin in clinical work, the research is adopted by comparing the efficacy and safety of the two dosage regimens to the patients with atrial fibrillation (AF) or pulmonary embolism (PE) by using different initial dosages of warfarin according to the warfarin 3mg and to the BMI.
METHODS 81 patients using oral warfarin were randomly assigned to two groups according to different kinds of dosage regimen. The control group included 42 cases started with 3 mg while research group included 39 cases, started with the initial warfarin dosage by the guide of body mass index (BMI) (BMI<25,3mg;25 BMI<30,4.5mg; BMI!30,6mg). Follow up one month, to compare the time that INR first stabilized at target range(2.0w3.0), the ratio within stabilized target range at different time, the time that INR stabilized at target range, the times to exceed therapeutic INR (INR>3.0), maintenance dose, and the incidence of bleeding or thrombosis episodes.
RESULTS
There was no statistical significance between the two groups in baseline characteristics included age, sex, height, weight, BMI, comorbid conditions, drug combination, Baseline INR, left atrial thrombus and pulmonary embolism. Comparing the safety between two groups: there were two cases bleeding slightly in control group and one case in research group, Both groups had no thrombotic events, There was no statistical significance between the two groups (P¼1.0). There were no statistical significance between the two groups in the incidence rate to exceed therapeutic INR in different time (P>0.05).There was 7 cases in control group to exceed therapeutic INR at day 15, and 13 cases in research group, There was no statistical significance between the two groups (P¼0.082, P>0.05). Comparing the effectiveness between two groups: compared with control group, the ratio to achieve therapeutic INR at day 3, day 5, day 7 were significantly higher in research group ( 38.9% vs. 11.9% at day 3, 51.3% vs. 23.8% at day 5, 71.8% vs. 45.2% at day 7), There was statistical significance between the two groups (P<0.05). Compared with control group, research group required a significantly shorter time to achieve therapeutic INR at the first time (5 days vs. 7 days), There was statistical significance between the two groups (P<0.05). There was no statistical significance between the two groups in the time that INR stabilized therapeutic INR (12 days in research group vs. 15 days in control group), but compared with control group, research group was faster. There was statistical significance between the two groups (P<0.05) in maintenance dose.
CONCLUSIONS compared with 3 mg as initial dose, It is more rapid and more effective to achieve therapeutic INR according to body mass index (BMI) guiding the initial warfarin dosage, and bleeding event did not add at the same time.
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Cholesterol in Remnant-Lipoproteins as Measured by Different Methods
